Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
JAG2
REST API REST API
Homo sapiens
JAG2 is differentially expressed in 277 experiments: 135 organism parts: amygdala, bone marrow, ... (133 more);, 233 disease states: normal, glioblastoma, ... (231 more);, 89 cell types 463 cell lines 43 compound treatments and 58 other conditions.
Orthologs ENSCING00000004617 (Ciona intestinalis)   JAG2 (Bos taurus)   JAG2 (Gallus gallus)   jag2 (Danio rerio)   JAG2 (2 of 2) (Danio rerio)   Jag2 (Rattus norvegicus)   Jag2 (Mus musculus)   Ser (Drosophila melanogaster)   jag2 (Xenopus laevis)   JAG2 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term plasma membrane, regulation of cell adhesion, protein binding, regulation of cell proliferation, membrane, spermatogenesis, growth factor activity, membrane fraction, cell differentiation, cell communication, Notch receptor processing, cell cycle, multicellular organismal development, integral to plasma membrane, regulation of cell migration, Notch binding, Notch signaling pathway, integral to membrane, calcium ion binding, morphogenesis of embryonic epithelium, regulation of apoptosis, in utero embryonic development, auditory receptor cell fate commitment, thymic T cell selection, skeletal system development, odontogenesis of dentine-containing tooth, respiratory system process, T cell differentiation
InterPro Term Notch_ligand_N, VWF_C, EGF_extracell, EGF, DSL, VWC_out, EGF_3, EGF-like, EGF-like_Ca-bd
UniProt Accession Q9Y219
Search EB-eye ENSG00000184916
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-17189, E-GEOD-15765, E-GEOD-803, E-GEOD-6573, E-GEOD-7224, ... (28 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, E-GEOD-18005, ... (39 experiments)

Factor Value U/D Experiments
HL-60
3
E-GEOD-5258, E-MTAB-37, E-GEOD-24147
LNCaP
2
E-GEOD-14464, E-GEOD-14990
AGS
2
E-MTAB-37, E-GEOD-15460
MCF-10A
2
E-TABM-420, E-GEOD-14990
MDA-MB-231
2
E-TABM-420, E-MTAB-62
MDA468
2
E-MEXP-440, E-MTAB-62
457 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-22373, E-GEOD-21668, E-GEOD-3920, E-MEXP-750, ... (48 experiments)

Factor Value U/D Experiments
macrophage
1
2
E-GEOD-3982, E-GEOD-22373, E-GEOD-8286
stromal cell
1
2
E-MEXP-2034, E-GEOD-3998, E-GEOD-10797
endothelial cell
1
2
E-GEOD-3920, E-GEOD-96, E-GEOD-19240
plasmacytoid dendritic cell
1
E-TABM-34
M1 macrophage
1
E-GEOD-5099
CD8+ T cell
1
E-MTAB-25
83 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-GEOD-1577, E-GEOD-16363, ... (60 experiments)

Factor Value U/D Experiments
glioblastoma
5
E-GEOD-6014, E-GEOD-4290, E-MTAB-37, E-MTAB-62, E-MEXP-567 ... (5 experiments)
prostate carcinoma
3
E-MTAB-62, E-MTAB-37, E-MEXP-1327
uterine fibroid
2
E-GEOD-7307, E-MTAB-62
AIDS-KS, HIV+, nodular (late) stage
1
2
E-MTAB-62, E-MEXP-66
adenocarcinoma
2
E-MTAB-62, E-MTAB-37
adrenocortical carcinoma
2
E-TABM-311, E-GEOD-10927
227 more value(s).


Compound treatment

studied in E-GEOD-1615, E-GEOD-5258, E-GEOD-5542, E-TABM-782, E-GEOD-3720, ... (27 experiments)

Factor Value U/D Experiments
none
1
8
E-GEOD-20719, E-TABM-782, E-GEOD-412, E-GEOD-5824, E-MEXP-1269, ... (9 experiments)
valproic acid
1
E-GEOD-1615
5-fluorouridine
1
1
E-GEOD-995
rapamycin
1
E-GEOD-5824
lipopolysaccharide
1
E-GEOD-3720
placebo
1
E-MEXP-1327
37 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
tunicamycin
1
1
E-GEOD-19519
thapsigargin
1
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, E-GEOD-16363, E-GEOD-1725 ... (5 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-994, E-MEXP-1251, ... (8 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-5999, E-GEOD-1638, E-GEOD-20033, E-MEXP-2359, ... (7 experiments)

Disease staging
studied in E-GEOD-1323, E-GEOD-19743, E-GEOD-3325, E-GEOD-21138, E-GEOD-3013 ... (5 experiments)

Environmental stress
studied in E-GEOD-3720, E-GEOD-4086

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-1643

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-MEXP-1482, E-GEOD-7578, E-MEXP-2340

Genotype
studied in E-MEXP-1996, E-TABM-1029, E-GEOD-22056, E-GEOD-2466, E-GEOD-17476, ... (10 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-1220, E-MEXP-2657, E-TABM-127, E-GEOD-20504, ... (10 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-TABM-325, E-GEOD-1926, E-GEOD-16363, E-GEOD-20876, E-GEOD-430, ... (28 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-9723, E-MEXP-561, E-GEOD-980

Injury
studied in E-GEOD-19743, E-GEOD-5372

Material type
studied in E-MEXP-455, E-MEXP-958

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

Organism
studied in E-GEOD-7540, E-GEOD-1801, E-TABM-84

Performer
studied in E-GEOD-2004, E-LGCL-5

Phenotype
studied in E-GEOD-19703, E-GEOD-21750, E-GEOD-1657, E-GEOD-17636

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

Replicate
studied in E-GEOD-10797, E-GEOD-18791, E-GEOD-10896

RNAi
studied in E-GEOD-12438, E-MEXP-1509, E-GEOD-1676, E-GEOD-3697, E-MEXP-1857, ... (6 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

Sampling time point
studied in E-GEOD-19743, E-GEOD-17400

Sex
studied in E-GEOD-1643, E-GEOD-19069, E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

Strain or line
studied in E-MEXP-1996, E-TABM-125

Survival time
studied in E-GEOD-19188

Test result
studied in E-GEOD-1926, E-TABM-276

Treatment
studied in E-GEOD-19246, E-GEOD-19815, E-GEOD-12198

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4922

Tumor size
studied in E-GEOD-8167

Vehicle
studied in E-GEOD-5258

Processing time: 0.325 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM